These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 19380599)

  • 1. Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.
    Murakami K; Okimoto T; Kodama M; Tanahashi J; Fujioka T; Ikeda F; Muraoka H; Takigawa M; Saika T; Hasegawa M; Kobayashi I
    Antimicrob Agents Chemother; 2009 Jul; 53(7):3097-9. PubMed ID: 19380599
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
    Yang JC; Lee PI; Hsueh PR
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1369-75. PubMed ID: 20658256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of 10-day Sitafloxacin-Containing Third-Line Rescue Therapies for Helicobacter pylori Strains Containing the gyrA Mutation.
    Mori H; Suzuki H; Matsuzaki J; Tsugawa H; Fukuhara S; Miyoshi S; Hirata K; Seino T; Matsushita M; Masaoka T; Kanai T
    Helicobacter; 2016 Aug; 21(4):286-94. PubMed ID: 26612407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
    Suzuki H; Nishizawa T; Muraoka H; Hibi T
    Antimicrob Agents Chemother; 2009 Apr; 53(4):1720-1. PubMed ID: 19188389
    [No Abstract]   [Full Text] [Related]  

  • 5. Effective therapeutic regimens in two South Asian countries with high resistance to major
    Miftahussurur M; Aftab H; Shrestha PK; Sharma RP; Subsomwong P; Waskito LA; Doohan D; Fauzia KA; Yamaoka Y
    Antimicrob Resist Infect Control; 2019; 8():40. PubMed ID: 30815255
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan.
    Hirata Y; Ohmae T; Yanai A; Sakitani K; Hayakawa Y; Yoshida S; Sugimoto T; Mitsuno Y; Akanuma M; Yamaji Y; Ogura K; Maeda S; Koike K
    Int J Antimicrob Agents; 2012 Apr; 39(4):352-5. PubMed ID: 22321702
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gemifloxacin can partially overcome quinolone resistance of H. pylori with gyrA mutation in Taiwan.
    Chang WL; Kao CY; Wu CT; Huang AH; Wu JJ; Yang HB; Cheng HC; Sheu BS
    Helicobacter; 2012 Jun; 17(3):210-5. PubMed ID: 22515359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
    Kim JM; Kim JS; Kim N; Jung HC; Song IS
    J Antimicrob Chemother; 2005 Nov; 56(5):965-7. PubMed ID: 16159928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levofloxacin-resistant Helicobacter pylori in Hong Kong.
    Lee CC; Lee VW; Chan FK; Ling TK
    Chemotherapy; 2008; 54(1):50-3. PubMed ID: 18073471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
    Touyama M; Higa F; Nakasone C; Shinzato T; Akamine M; Haranaga S; Tateyama M; Nakasone I; Yamane N; Fujita J
    J Antimicrob Chemother; 2006 Dec; 58(6):1279-82. PubMed ID: 17056610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.
    Yamamoto T; Takano T; Higuchi W; Nishiyama A; Taneike I; Yoshida K; Kanda H; Imamura Y
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4261-6. PubMed ID: 21730117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gatifloxacin resistance and mutations in gyra after unsuccessful Helicobacter pylori eradication in Japan.
    Nishizawa T; Suzuki H; Kurabayashi K; Masaoka T; Muraoka H; Mori M; Iwasaki E; Kobayashi I; Hibi T
    Antimicrob Agents Chemother; 2006 Apr; 50(4):1538-40. PubMed ID: 16569878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the level of resistance and identification of a resistance conferring mutation in GyrB.
    Rimbara E; Noguchi N; Kawai T; Sasatsu M
    Helicobacter; 2012 Feb; 17(1):36-42. PubMed ID: 22221614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Activity of Sitafloxacin and Additional Newer Generation Fluoroquinolones Against Ciprofloxacin-Resistant Neisseria gonorrhoeae Isolates.
    Hamasuna R; Ohnishi M; Matsumoto M; Okumura R; Unemo M; Matsumoto T
    Microb Drug Resist; 2018; 24(1):30-34. PubMed ID: 28581359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of delafloxacin against clinical levofloxacin-resistant Helicobacter pylori isolates.
    Luzarraga V; Cremniter J; Plouzeau C; Michaud A; Broutin L; Burucoa C; Pichon M
    J Antimicrob Chemother; 2024 Oct; 79(10):2633-2639. PubMed ID: 39126340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan.
    Hung KH; Sheu BS; Chang WL; Wu HM; Liu CC; Wu JJ
    Helicobacter; 2009 Feb; 14(1):61-5. PubMed ID: 19191898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan.
    Miyachi H; Miki I; Aoyama N; Shirasaka D; Matsumoto Y; Toyoda M; Mitani T; Morita Y; Tamura T; Kinoshita S; Okano Y; Kumagai S; Kasuga M
    Helicobacter; 2006 Aug; 11(4):243-9. PubMed ID: 16882327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.
    Cheng AF; Yew WW; Chan EW; Chin ML; Hui MM; Chan RC
    Antimicrob Agents Chemother; 2004 Feb; 48(2):596-601. PubMed ID: 14742214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence and mechanisms of resistance to fluoroquinolones in Helicobacter pylori strains from patients living in Belgium.
    Bogaerts P; Berhin C; Nizet H; Glupczynski Y
    Helicobacter; 2006 Oct; 11(5):441-5. PubMed ID: 16961806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility.
    Cattoir V; Nectoux J; Lascols C; Deforges L; Delchier JC; Megraud F; Soussy CJ; Cambau E
    Int J Antimicrob Agents; 2007 Apr; 29(4):389-96. PubMed ID: 17303392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.